Počet záznamů: 1  

The Determining Role of Mitochondrial Reactive Oxygen Species Generation and Monoamine Oxidase Activity in Doxorubicin-Induced Cardiotoxicity

  1. 1.
    SYSNO ASEP0541609
    Druh ASEPJ - Článek v odborném periodiku
    Zařazení RIVJ - Článek v odborném periodiku
    Poddruh JČlánek ve WOS
    NázevThe Determining Role of Mitochondrial Reactive Oxygen Species Generation and Monoamine Oxidase Activity in Doxorubicin-Induced Cardiotoxicity
    Tvůrce(i) Antonucci, S. (IT)
    Di Sante, M. (IT)
    Tonolo, F. (IT)
    Pontarollo, L. (IT)
    Scalcon, V. (IT)
    Alánová, Petra (FGU-C) RID, ORCID
    Menabo, R. (IT)
    Carpi, A. (IT)
    Bindoli, A. (IT)
    Rigobello, M. P. (IT)
    Giorgio, M. (IT)
    Kaludercic, N. (IT)
    Di Lisa, F. (IT)
    Zdroj.dok.Antioxidants & Redox Signaling. - : Mary Ann Liebert - ISSN 1523-0864
    Roč. 34, č. 7 (2021), s. 531-550
    Poč.str.20 s.
    Jazyk dok.eng - angličtina
    Země vyd.US - Spojené státy americké
    Klíč. slovadoxorubicin ; cardiomyopathy ; mitochondria ; monoamine oxidase ; reactive oxygen species (ROS)
    Vědní obor RIVED - Fyziologie
    Obor OECDPhysiology (including cytology)
    Způsob publikováníOmezený přístup
    Institucionální podporaFGU-C - RVO:67985823
    UT WOS000547813800001
    EID SCOPUS85100745267
    DOI10.1089/ars.2019.7929
    AnotaceAims: Doxorubicin cardiomyopathy is a lethal pathology characterized by oxidative stress, mitochondrial dysfunction, and contractile impairment, leading to cell death. Although extensive research has been done to understand the pathophysiology of doxorubicin cardiomyopathy, no effective treatments are available. We investigated whether monoamine oxidases (MAOs) could be involved in doxorubicin-derived oxidative stress, and in the consequent mitochondrial, cardiomyocyte, and cardiac dysfunction. Results: We used neonatal rat ventricular myocytes (NRVMs) and adult mouse ventricular myocytes (AMVMs). Doxorubicin alone (i.e., 0.5 μM doxorubicin) or in combination with H2O2 induced an increase in mitochondrial formation of reactive oxygen species (ROS), which was prevented by the pharmacological inhibition of MAOs in both NRVMs and AMVMs. The pharmacological approach was supported by the genetic ablation of MAO-A in NRVMs. In addition, doxorubicin-derived ROS caused lipid peroxidation and alterations in mitochondrial function (i.e., mitochondrial membrane potential, permeability transition, redox potential), mitochondrial morphology (i.e., mitochondrial distribution and perimeter), sarcomere organization, intracellular [Ca2+] homeostasis, and eventually cell death. All these dysfunctions were abolished by MAO inhibition. Of note, in vivo MAO inhibition prevented chamber dilation and cardiac dysfunction in doxorubicin-treated mice.
    Innovation and Conclusion: This study demonstrates that the severe oxidative stress induced by doxorubicin requires the involvement of MAOs, which modulate mitochondrial ROS generation. MAO inhibition provides evidence that mitochondrial ROS formation is causally linked to all disorders caused by doxorubicin in vitro and in vivo. Based upon these results, MAO inhibition represents a novel therapeutic approach for doxorubicin cardiomyopathy.
    PracovištěFyziologický ústav
    KontaktLucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400
    Rok sběru2022
    Elektronická adresahttps://doi.org/10.1089/ars.2019.7929
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.